* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download AWOtherapeutics
Survey
Document related concepts
Discovery and development of angiotensin receptor blockers wikipedia , lookup
Toxicodynamics wikipedia , lookup
Nicotinic agonist wikipedia , lookup
Neuropharmacology wikipedia , lookup
5-HT3 antagonist wikipedia , lookup
Adherence (medicine) wikipedia , lookup
Psychopharmacology wikipedia , lookup
Cannabinoid receptor antagonist wikipedia , lookup
Psychedelic therapy wikipedia , lookup
Discovery and development of antiandrogens wikipedia , lookup
Neuropsychopharmacology wikipedia , lookup
NK1 receptor antagonist wikipedia , lookup
Transcript
DRUG THERAPY OF AIRFLOW OBSTRUCTION PROFESSOR B J LIPWORTH • Preventers (anti-inflammatory) • Relievers (bronchodilators) THE INFLAMMATORY CASCADE Genetic predisposition + Trigger factor (e.g. viral, allergen, chemicals) Airway inflammation Mediators (e.g. histamine, leukotriene) Twitchy smooth muscle (Hyper-reactivity) • Avoidance • Anti-inflammatory - corticosteroid • Anti-leukotriene Anti-histamine • Bronchodilators - 2-agonists THE ASTHMA TREATMENT PYRAMID Oral Steroid Controller (Additive to ICS ) Preventer Reliever Theophylline Leukotriene-antagonist Long-acting 2-agonist Inhaled steroid ( Cromogylcate ?) Short-acting 2-agonist PRN Increasing severity BTS Asthma Guidelines Step 4 Step 3 Step 1 intermittent Step 2 mild persistent moderate persistent severe persistent Short-acting ß2 agonists prn Inhaled steroids Add on LABA Add on LTRA/Theo ANTI-INFLAMMATORY: CORTICOSTEROIDS • Used in asthma and COPD • Oral steroid (prednisolone) - low therapeutic ratio - only used for acute exacerbations • Inhaled steroid (beclomethasone) - higher therapeutic ratio - used for maintenance therapy • Optimise lung delivery - large volume spacer Lung deposition of HFA-BDP, fluticasone and CFC-BDP MMAD = 1.1 µm MMAD = 2.5 µm MMAD = 3.5 µm Actions of a spacer device • Avoids coordination problems with pMDI • Reduces oropharyngeal and laryngeal side effects • Reduces systemic absorption from swallowed fraction • Acts a holding chamber for aerosol • Reduces particle size and velocity • Improves lung deposition ANTI-INFLAMMATORY: CROMONES • Only used in asthma (eg Cromoglycate) • Mast cell stabiliser - weak anti-inflammatory cf steroids • Cromoglycate effective in atopic children (exercise asthma) • Inhaled route only (compliance with QID dosing ) • No longer used due to poor efficacy ANTI-INFLAMMATORY: LEUKOTRIENE RECEPTOR ANTAGONISTS • Only used in asthma: bronchodilator + anti-inflammatory • Montelukast - oral route,once daily, high therapeutic ratio • Less potent anti-inflammatory than inhaled steroid • 2nd line: complimenatary non steroidal ant-inflammatory additive to inhaled steroid • Effective in exercise induced asthma • Also effective in allergic rhinitis ( with anti-histamine ) ANTI-INFLAMMATORY: ANTIHISTAMINES • H1 receptor antagonists • Oral route • Only of value when known allergenic trigger (e.g. HDM ,pollen or cat) -ie in atopic asthma • 1st generation :Chlorpheniramine-sedative • 2nd generation: Cetirizine,Loratadine-non sedative • 3rd generation: Levocetirizine,Desloratadine - non sedative • More effective in allergic rhinitis than asthma • Additive effects when given together with leukotreine antagonist ANTI-INFLMMATORY Anti-IgE • Anti-IgE monoclonal antibody : Omalizumab (Xolair) • Omalizumab inhibits the binding to the high-affinity IgE receptor and inhibit mediator release from basophils and mast cells . • Injection every 2-4 weeks . • For patients with severe persistent allergic asthma despite max therapy –ie step 5 . • Very expensive . • No effect on pulmonary function but reduces exacerbations . BRONCHODILATORS: 2-AGONISTS Stimulate bronchial smooth muscle 2-receptors: cAMP Short-acting - salbutamol Long-acting – salmeterol / formoterol Combination inhalers-eg Seretide / Symbicort Used in asthma and COPD High therapeutic ratio when given by inhaled route Systemic 2 effects when given systemically or at high inhaled doses • High nebulised doses given in acute attack • • • • • • • Muscarinic (cholinergic) receptors M1-receptors enhance the cholinergic reflex M2-receptors inhibit acetylcholine release M3-receptors mediate bronchoconstriction and mucus secretion BRONCHODILATORS: ANTICHOLINERGICS • Block post junctional end plate M3 receptors • Ipratropium qid , Tiotropium od - inhaled route only - high therapeutic ratio • Used in COPD - less effective in asthma • High nebulised doses of ipratropium used in acute COPD and in acute asthma BRONCHODILATOR/ANTINFLAMMATORY :METHYLXANTHINES • Oral (Theophylline) for maintenance therapy • SR formulation useful for nocturnal dips • Used as add to inhaled steroid as complimentary non steroidal anti-inflammatory • IV (Aminophylline) for acute attacks • Non selective phosphodiesterase inhibitor (cAMP) • Adenosine antagonist • Low therapeutic ratio - P450 drug interactions (e.g. erythromycin) • Used in asthma and COPD Anti-inflammatory :PDE4 inhibitors • • • • • Roflumilast –oral tablet od Indicated for COPD only Minimal effect on FEV1 Reduces exacerbations –additive to LABA or LAMA Adverse effects : Nausea/Diarrhoea/Headache/Weight loss • ? Place in COPD guidelines as add on to ICS/LABA/LAMA Mucolytics • Oral carbocisteine , erdosteine • To reduce sputum viscosity and aide sputum expectoration [and reduce exacerbations ] in COPD • Rarely used –only as add on to other treatments TREATMENT OF CHRONIC ASTHMA • AIMS: Abolish sympt, min 2-use, normalise FEV1, reduce PEF variability, reduce exac, prevent long term airway remod • Avoid triggers • Suppress inflammatory cascade with inh steroid +/- non steroidal anti-inflamm therapy –eg theophylline ,antileukotriene ,anti-histamine • Stabilise smooth muscle with LABA –only once optimal antiinflamm therapy in place TREATMENT OF ACUTE ASTHMA • Oral prednisolone (or iv hydrocortisone ) • Nebulised high dose salbutamol, ± Neb ipratropium, ± iv aminophylline/magnesium • 60% O2 • ITU Assisted mecahnical intubated ventilation if falling PaO2 and rising PaCO2 - never use respiratory stimulant Non-pharmacological intervention: smoking cessation Never smoked or not susceptible to smoke FEV1 (% of value at age 25) 100 75 Smoked regularly and susceptible to its effects Stopped at 45 50 Disability 25 Stopped at 65 Death 0 25 50 Age (years) 75 Fletcher et al., 1977 TREATMENT OF STABLE COPD • Prevent FEV1 decline - stop smoking • Treat reversible component - Inhaled steroid - Short/Long acting beta-2 agonists - Short/Long acting anticholinergics -Theophylline • Pulm rehab • Vaccination –influenza/pneumococcal • Domiciliary O2 to prevent cor pulmonale • Venesection for polycythaemia • Lung volume reduction surgery for highly slected patients TREATMENT OF ACUTE COPD • • • • • • • Nebulised high dose salbutamol + ipratropium Oral prednisolone Antibiotic (amoxycillin) if infection 24-28% O2 Respiratory stimulant (doxapram) to improve ventilation Non invasive ventilation instead of doxapram ITU Intubated assisted ventilation only if reversible component (eg pneumonia)